Literature DB >> 1768813

Anemia ameliorates progressive renal injury in experimental DOCA-salt hypertension.

H M Lafferty1, D L Garcia, H G Rennke, J L Troy, S Anderson, B M Brenner.   

Abstract

To explore the role of systemic hematocrit in the vascular adaptations which characterize desoxycorticosterone-salt hypertension, studies were performed in three groups of rats with uninephrectomy, desoxycorticosterone administration, and 1% saline in the drinking water. One group received recombinant human erythropoietin to increase hematocrit, and another group was subjected to phlebotomy and fed a low-iron diet to induce anemia. Control rats exhibited systemic and glomerular capillary hypertension, proteinuria, and substantial glomerular sclerosis at 8 wk. Erythropoietin modestly increased hematocrit and blood pressure and substantially aggravated glomerular capillary pressure, proteinuria, and glomerular sclerosis. In contrast, reduction of hematocrit with a low-iron diet significantly attenuated systemic and glomerular hypertension, proteinuria, and sclerosis. It was concluded that the pace of progression of glomerular injury can be limited by chronic reduction in hematocrit, which effectively ameliorates both systemic and glomerular hypertension in this model of salt-sensitive hypertensive renal disease.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1768813     DOI: 10.1681/ASN.V1101180

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   10.121


  2 in total

1.  Tubular deficiency of von Hippel-Lindau attenuates renal disease progression in anti-GBM glomerulonephritis.

Authors:  Franziska Theilig; Anne Kathrin Enke; Brigitte Scolari; Danny Polzin; Sebastian Bachmann; Robert Koesters
Journal:  Am J Pathol       Date:  2011-09-15       Impact factor: 4.307

2.  r.hu-erythropoietin (EPO) treatment of pre-ESRD patients slows the rate of progression of renal decline.

Authors:  Mihály Tapolyai; Satoshi Kadomatsu; Manuel Perera-Chong
Journal:  BMC Nephrol       Date:  2003-06-17       Impact factor: 2.388

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.